ArticleFrontiers in immunology2025
Identification of the gene signatures related to NK/T cell communication to evaluate the tumor microenvironment and prognostic outcomes of patients with prostate adenocarcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A three-protein serum risk score for predicting immunotherapy response and prognosis in non-small cell lung cancer.International journal of clinical and experimental pathology · 2026Article
- Construction of a Prognostic Model of Prostate Cancer Based on Immune and Metabolic Genes and Experimental Validation of the Gene AK5.Oncology research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate adenocarcinoma (PRAD) is a leading cause of male mortality, with NK/T cell communication being key areas of the research. Methods: The Seurat package was utilized to normalize and reduce the dimensionality of the single-cell data, and CellMarker 2.0 was employed for cell annotation. CellChat was utilized to construct the ligand-receptor interaction network of cell subsets. Differentially expressed genes (DEGs) were filtered by the limma package. Univariate Cox and the LASSO regression in the glmnet package were used to obtain biomarkers and develop a risk model. The survminer package was used to calculate the optimal threshold for dividing patients into high-risk and low-risk groups, and then Kaplan-Meier (KM) survival analysis was performed. Single-sample GSEA (ssGSEA), TIMER, and ESTIMATE packages were employed for immune infiltration analysis. Pathway analysis was conducted for the low- and high-risk groups using GSEA. Immunotherapy responses were evaluated by adopting TIDE method. Additional cellular validation (quantitative real-time PCR, CCK-8, Transwell, and scratch assay) was implemented to confirm the effects of feature genes on PRAD. Results: Compared with the benign group, NK/T cells were the cell type with the greatest changes in the tumor group, and their communication intensity was relatively high among all cell types. A RiskScore model was constructed as follows: Conclusion: The current research reveals key communication genes in PRAD, offering new possibilities for the exploration of new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.